Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGSWW) Cash & Equivalents (2020 - 2025)

GeneDx Holdings has reported Cash & Equivalents over the past 6 years, most recently at $105.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $105.0 million for Q4 2025, up 23.22% from a year ago — trailing twelve months through Dec 2025 was $105.0 million (up 23.22% YoY), and the annual figure for FY2025 was $105.0 million, up 23.22%.
  • Cash & Equivalents for Q4 2025 was $105.0 million at GeneDx Holdings, up from $96.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for WGSWW hit a ceiling of $461.3 million in Q3 2021 and a floor of $26.5 million in Q2 2021.
  • Median Cash & Equivalents over the past 5 years was $99.7 million (2023), compared with a mean of $153.3 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 40363.55% in 2021 and later tumbled 69.06% in 2022.
  • GeneDx Holdings' Cash & Equivalents stood at $400.6 million in 2021, then tumbled by 69.06% to $123.9 million in 2022, then dropped by 19.57% to $99.7 million in 2023, then dropped by 14.52% to $85.2 million in 2024, then increased by 23.22% to $105.0 million in 2025.
  • The last three reported values for Cash & Equivalents were $105.0 million (Q4 2025), $96.0 million (Q3 2025), and $74.1 million (Q2 2025) per Business Quant data.